Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

leo pharma pty ltd - methylprednisolone aceponate, quantity: 1 mg/g - cream - excipient ingredients: butylated hydroxytoluene; purified water; hard fat; cetostearyl alcohol; glyceryl monostearate; glycerol; disodium edetate; peg-40 stearate; benzyl alcohol; decyl oleate; medium chain triglycerides - topical treatment of eczema and psoriasis.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

dr. reddy's laboratories inc - methylprednisolone sodium succinate (unii: lec9gky20k) (methylprednisolone - unii:x4w7zr7023) - when oral therapy is not feasible, and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of methylprednisolone sodium succinate for injection, usp is indicated as follows: allergic states: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. dermatologic diseases : bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyp

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

praxgen pharmaceuticals llc - methylprednisolone (unii: x4w7zr7023) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone tablets, usp are indicated in the following conditions: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis synovitis of osteoarthritis acute nonspecific tenosynovitis post-traumatic osteoarthritis psoriatic arthritis epicondylitis a

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

amneal pharmaceuticals llc - methylprednisolone (unii: x4w7zr7023) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone tablets are indicated in the following conditions: 1.      endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2.      rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis synovitis of osteoarthritis acute nonspecific tenosynovitis post-traumatic osteoarthritis psoriatic arthritis epicondylitis acute gouty arthritis 3.      collagen diseases during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus systemic dermatomyositis (polymyositis) acute rheumatic carditis 4.      dermatologic diseases bullous dermatitis herpetiformis severe erythema multiforme (stevens-johnson syndrome) severe seborrheic dermatitis exfoliative dermatitis mycosis fungoides pemphigus severe psoriasis 5.      allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: seasonal or perennial allergic rhinitis drug hypersensitivity reactions serum sickness contact dermatitis bronchial asthma atopic dermatitis 6.      ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia keratitis optic neuritis allergic conjunctivitis chorioretinitis iritis and iridocyclitis 7.      respiratory diseases symptomatic sarcoidosis berylliosis loeffler’s syndrome not manageable by other means fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis 8.      hematologic disorders idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired (autoimmune) hemolytic anemia erythroblastopenia (rbc anemia) congenital (erythroid) hypoplastic anemia 9.      neoplastic diseases for palliative management of: leukemias and lymphomas in adults acute leukemia of childhood 10.  edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.  gastrointestinal diseases to tide the patient over a critical period of the disease in: ulcerative colitis regional enteritis 12.  nervous system acute exacerbations of multiple sclerosis 13.  miscellaneous tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. trichinosis with neurologic or myocardial involvement. systemic fungal infections and known hypersensitivity to components.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - methylprednisolone (unii: x4w7zr7023) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone tablets are indicated in the following conditions:   primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis synovitis of osteoarthritis acute nonspecific tenosynovitis post-traumatic osteoarthritis psoriatic arthritis epicondylitis acute gouty arthritis during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus systemic dermatomyositis (polymyositis) acute rheumatic cardit

Israel - Tiếng Anh - Ministry of Health

genmedix , israel - methylprednisolone as hemisuccinate - lyophilized powder for solution for injection or infusion - methylprednisolone as hemisuccinate 1 g/vial - methylprednisolone - methylprednisolone - methylprednisolone mylan is indicated to treat any condition in which iv corticosteroid treatment is required such as: endocrine disorders, rheumatic disorders, collagen diseases, immune complex diseases, dermatologic diseases, allergic states, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, management of neoplastic diseases, edematous states, nervous system disorders and organ transplantation.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - methylprednisolone aceponate, quantity: 1 mg/g - ointment - excipient ingredients: white soft paraffin; microcrystalline wax; liquid paraffin; hydrogenated castor oil - tanilone fatty ointment is indicated for the topical treatment of eczema and psoriasis in adults and children.

Canada - Tiếng Anh - Health Canada

teva canada limited - methylprednisolone (methylprednisolone sodium succinate) - powder for solution - 1g - methylprednisolone (methylprednisolone sodium succinate) 1g - adrenals

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

leo pharma pty ltd - methylprednisolone aceponate, quantity: 0.1 % - lotion - excipient ingredients: steareth-21; benzyl alcohol; glycerol; purified water; disodium edetate; steareth-2; medium chain triglycerides - for the topical treatment of eczema in children and adults. indications as at 7 december 2001. topical treatment for eczema and psoriasis in adults and children.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

leo pharma limited - methylprednisolone aceponate 0.1%{relative};   - topical cream - 0.1 % - active: methylprednisolone aceponate 0.1%{relative}   excipient: benzyl alcohol butylated hydroxytoluene cetostearyl alcohol decyl oleate glycerol glyceryl monostearate hard fat macrogol stearate 2000 purified water sodium edetate softisan 378 - atopic dermatitis (endogenous eczema, neurodermatitis), contact eczema, degenerative, dyshidrotic, vulgar eczema, eczema in children.